Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics, Inc. is committed to creating new consumer experiences with distinct recreational, medical and wellness-oriented cannabis and non-cannabis products, with an emphasis on life science-based innovation and production excellence. Emerald’s three distinct operating assets are designed to uniquely serve the Canadian marketplace and international opportunities.

Recent News

  • Emerald Health Therapeutics Promotes Two Executives to Senior Roles

    Vancouver, British Columbia--(Newsfile Corp. - February 5, 2021) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") has promoted Orville Bovenschen to the position of Senior Vice President, Operations and Rebecca Wong to Senior Vice President, Quality & Regulatory Affairs.Mr. Bovenschen has over 16 years of progressive experience in financial management, project and operations management, and strategy development and operational planning, including risk management. With Emerald since 2017, he has overseen the planning and management of all...

    2021-02-05 7:00 AM EST
  • Emerald Health Therapeutics Settles Outstanding Amounts

    Vancouver, British Columbia--(Newsfile Corp. - January 13, 2021) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") today announced that it has settled all outstanding amounts owing to the original vendors (the "Vendors") in connection with Emerald's 2018 acquisition of Verdélite Sciences, Inc. ("Verdélite Sciences") and Verdélite Property Holdings, Inc. ("Verdélite Property" and, together with Verdélite Sciences, the "Subsidiaries").The Subsidiaries were purchased by Emerald from the Vendors in 2018 and a portion of the purchase price payable to the...

    2021-01-13 7:00 AM EST
  • Emerald Health Therapeutics' Partner STENOCARE Makes First Delivery of Medical Cannabis Oil to Swedish Patients

    Vancouver, British Columbia--(Newsfile Corp. - December 29, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") today announced that its partner, STENOCARE A/S, completed its first shipment and delivery of Emerald medical cannabis oil to patients in Sweden. In Sweden, several patients diagnosed with chronic nervous system pain, spasms and nausea from chemotherapy have via their doctor previously applied for a prescription for treatment with medical cannabis oil. Emerald and STENOCARE announced on September 8th approval from the...

    2020-12-29 7:00 AM EST
  • Emerald Health Therapeutics Introduces High Potency SYNC(TM) 100 CBD Oil

    Vancouver, British Columbia--(Newsfile Corp. - December 17, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") has launched and made its first shipment of its new SYNC™ 100 CBD oil to the province of Saskatchewan. Shipments to Alberta and BC are scheduled for next week, with product expected to be available for purchase online and in licensed stores before the new year.This natural flavoured whole-flower cannabis oil is made with all-natural ingredients and vegan, 100%-organic, palm-free coconut oil....

    2020-12-17 7:00 AM EST
  • Emerald Health Therapeutics Terminates Agreement for Sale of Quebec Cannabis Business

    Vancouver, British Columbia--(Newsfile Corp. - December 4, 2020) -  Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") today announced that it has terminated its share purchase agreement dated July 30, 2020 (the "Agreement") with Quinto Resources Inc. ("Quinto") in respect of the proposed sale of Emerald's wholly-owned subsidiaries, Verdélite Sciences, Inc. ("Verdélite Sciences") and Verdélite Property Holdings, Inc. ("Verdélite Property" and, together with Verdélite Sciences, the "Subsidiaries"). The Subsidiaries together own and operate a premium 88,000 square foot craft...

    2020-12-04 5:02 PM EST
  • Emerald Health Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

    Vancouver, British Columbia--(Newsfile Corp. - December 1, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") has released its financial results for the three and nine months ended September 30, 2020. Full versions of Emerald's unaudited condensed interim consolidated financial statements and management discussion and analysis can be found on SEDAR at www.sedar.com."The pivotal recent event for Emerald has been the completion of our divestment of our ownership interest in Pure Sunfarms. We received $60M in cash,...

    2020-12-01 7:00 AM EST
  • Emerald Health Therapeutics Announces Full Prepayment of Convertible Debentures

    Vancouver, British Columbia--(Newsfile Corp. - November 24, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (the "Company") has fully prepaid in cash all amounts owing under the convertible debentures issued to certain Canadian institutional accredited investors (the "Debentureholders") by the Company on September 9, 2019 (the "Convertible Debentures"). As a result, the Convertible Debentures are now terminated and the Company has no further obligations thereunder.The Convertible Debentures accrued interest at a rate of 5% per annum and were...

    2020-11-24 7:00 AM EST
  • RETRANSMISSION: Emerald Health Therapeutics Completes Sale of Pure Sunfarms Interest and Achieves Pivotal Milestone in Transforming its Business

    Vancouver, British Columbia--(Newsfile Corp. - November 2, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (the "Company") has completed the previously disclosed sale of its 41.3% interest in Pure Sunfarms Corp. ("PSF") to Village Farms International, Inc. ("Village Farms") (NASDAQ: VFF) (TSX: VFF) for consideration of $79,900,000.As previously announced by the Company, on September 8, 2020, it entered into a share purchase agreement (the "Share Purchase Agreement") with Village Farms in respect of the sale of the Company's...

    2020-11-02 9:11 AM EST